Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis

被引:139
|
作者
Ajose, Olawale [2 ]
Mookerjee, Siddharth [3 ]
Mills, Edward J. [4 ]
Boulle, Andrew
Ford, Nathan [1 ,5 ]
机构
[1] Med Sans Frontieres, CH-1211 Geneva, Switzerland
[2] Clinton Hlth Access Initiat, Dar Es Salaam, Tanzania
[3] Univ London Imperial Coll Sci Technol & Med, Natl Ctr Infect Prevent & Management, London, England
[4] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada
[5] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa
关键词
protease inhibitors; second-line failure; viraemia; virological suppression; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; ROLL-OUT; HIV; MORTALITY; EFFICACY; FAILURE; PROGRAM; COST; LOPINAVIR/RITONAVIR;
D O I
10.1097/QAD.0b013e328351f5b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Methods: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Conclusion: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 938
页数:10
相关论文
共 50 条
  • [1] Effectiveness of Pediatric Antiretroviral Therapy in Resource-Limited Settings: A Systematic Review and Meta-analysis
    Ciaranello, Andrea L.
    Chang, Yuchiao
    Margulis, Andrea V.
    Bernstein, Adam
    Bassett, Ingrid V.
    Losina, Elena
    Walensky, Rochelle P.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (12) : 1915 - 1927
  • [2] Second-line antiretroviral therapy in resource-limited settings:: the experience of Medecins Sans Frontieres
    Pujades-Rodriguez, Mar
    O'Brien, Daniel
    Humblet, Pierre
    Calmy, Alexandra
    AIDS, 2008, 22 (11) : 1305 - 1312
  • [3] Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis
    Brinkhof, Martin W. G.
    Pujades-Rodriguez, Mar
    Egger, Matthias
    PLOS ONE, 2009, 4 (06):
  • [4] Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
    Boyd, Mark A.
    Cooper, David A.
    AIDS, 2007, 21 : S55 - S63
  • [5] Raltegravir in second-line ART in resource-limited settings
    Haas, Andreas D.
    Keiser, Olivia
    LANCET HIV, 2016, 3 (06): : E240 - E241
  • [6] Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring
    Keiser, Olivia
    Tweya, Hannock
    Boulle, Andrew
    Braitstein, Paula
    Schechter, Mauro
    Brinkhof, Martin W. G.
    Dabis, Francois
    Tuboi, Suely
    Sprinz, Eduardo
    Pujades-Rodriguez, Mar
    Calmy, Alexandra
    Kumarasamy, Nagalingeswaran
    Nash, Denis
    Jahn, Andreas
    MacPhail, Patrick
    Luethy, Ruedi
    Wood, Robin
    Egger, Matthias
    AIDS, 2009, 23 (14) : 1867 - 1874
  • [7] Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings
    Marukutira, Tafireyi
    Wood, Brian R.
    AIDS, 2021, 35 (09) : 1505 - 1507
  • [8] Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings
    Hosseinipour, Mina C.
    Gupta, Ravindra K.
    Van Zyl, Gert
    Eron, Joseph J.
    Nachega, Jean B.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 207 : S49 - S56
  • [9] Second-line Antiretroviral Treatment in Resource-Limited Settings: Abandon Lopinavir/Ritonavir Monotherapy or Search for New Candidates?
    Hu, Zhiliang
    Li, Zhen
    Yang, Yongfeng
    Wei, Hongxia
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (05) : 852 - U204
  • [10] Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings
    Aurpibul, Linda
    Puthanakit, Thanyawee
    CURRENT PEDIATRIC REVIEWS, 2011, 7 (03) : 180 - 187